These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Caspofungin at catheter lock concentrations eradicates mature biofilms of Candida lusitaniae and Candida guilliermondii. Simitsopoulou M; Kyrpitzi D; Velegraki A; Walsh TJ; Roilides E Antimicrob Agents Chemother; 2014 Aug; 58(8):4953-6. PubMed ID: 24890585 [TBL] [Abstract][Full Text] [Related]
25. Postantifungal effect of micafungin against Candida albicans, Candida dubliniensis and Candida africana in the presence and absence of serum. Kardos T; Saleh Q; Kovács R; Gesztelyi R; Kardos G; Bozó A; Tóth Z; Majoros L New Microbiol; 2017 Oct; 40(4):286-288. PubMed ID: 28994449 [TBL] [Abstract][Full Text] [Related]
26. Comparison between the EUCAST procedure and the Etest for determination of the susceptibility of Candida species isolates to micafungin. Marcos-Zambrano LJ; Escribano P; Rueda C; Zaragoza Ó; Bouza E; Guinea J Antimicrob Agents Chemother; 2013 Nov; 57(11):5767-70. PubMed ID: 23979756 [TBL] [Abstract][Full Text] [Related]
27. Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis. Gil-Alonso S; Jauregizar N; Eraso E; Quindós G PLoS One; 2015; 10(7):e0132730. PubMed ID: 26168269 [TBL] [Abstract][Full Text] [Related]
28. [In vitro antifungal activity of micafungin]. Quindós G; Eraso E; Javier Carrillo-Muñoz A; Cantón E; Pemán J Rev Iberoam Micol; 2009 Mar; 26(1):35-41. PubMed ID: 19463275 [TBL] [Abstract][Full Text] [Related]
29. Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method. Espinel-Ingroff A; Alvarez-Fernandez M; Cantón E; Carver PL; Chen SC; Eschenauer G; Getsinger DL; Gonzalez GM; Govender NP; Grancini A; Hanson KE; Kidd SE; Klinker K; Kubin CJ; Kus JV; Lockhart SR; Meletiadis J; Morris AJ; Pelaez T; Quindós G; Rodriguez-Iglesias M; Sánchez-Reus F; Shoham S; Wengenack NL; Borrell Solé N; Echeverria J; Esperalba J; Gómez-G de la Pedrosa E; García García I; Linares MJ; Marco F; Merino P; Pemán J; Pérez Del Molino L; Roselló Mayans E; Rubio Calvo C; Ruiz Pérez de Pipaon M; Yagüe G; Garcia-Effron G; Guinea J; Perlin DS; Sanguinetti M; Shields R; Turnidge J Antimicrob Agents Chemother; 2015 Nov; 59(11):6725-32. PubMed ID: 26282428 [TBL] [Abstract][Full Text] [Related]
30. In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. Cantón E; Pemán J; Valentín A; Espinel-Ingroff A; Gobernado M Antimicrob Agents Chemother; 2009 Jul; 53(7):3108-11. PubMed ID: 19380590 [TBL] [Abstract][Full Text] [Related]
31. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Cantón E; Espinel-Ingroff A; Pemán J; del Castillo L Antimicrob Agents Chemother; 2010 May; 54(5):2194-7. PubMed ID: 20145083 [TBL] [Abstract][Full Text] [Related]
32. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464 [TBL] [Abstract][Full Text] [Related]
33. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029 [TBL] [Abstract][Full Text] [Related]
34. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Di Bonaventura G; Spedicato I; Picciani C; D'Antonio D; Piccolomini R Antimicrob Agents Chemother; 2004 Nov; 48(11):4453-6. PubMed ID: 15504881 [TBL] [Abstract][Full Text] [Related]
35. Activity of exogenous tyrosol in combination with caspofungin and micafungin against Candida parapsilosis sessile cells. Kovács R; Tóth Z; Nagy F; Daróczi L; Bozó A; Majoros L J Appl Microbiol; 2017 Jun; 122(6):1529-1536. PubMed ID: 28321957 [TBL] [Abstract][Full Text] [Related]
36. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Espinel-Ingroff A Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349 [TBL] [Abstract][Full Text] [Related]
37. Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua. Kovács R; Gesztelyi R; Berényi R; Domán M; Kardos G; Juhász B; Majoros L J Med Microbiol; 2014 Feb; 63(Pt 2):186-194. PubMed ID: 24184471 [TBL] [Abstract][Full Text] [Related]
38. Frequency of the Paradoxical Effect Measured Using the EUCAST Procedure with Micafungin, Anidulafungin, and Caspofungin against Candida Species Isolates Causing Candidemia. Marcos-Zambrano LJ; Escribano P; Sánchez-Carrillo C; Bouza E; Guinea J Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799221 [TBL] [Abstract][Full Text] [Related]
39. Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3. Varga I; Sóczó G; Kardos G; Majoros L J Antimicrob Chemother; 2008 Jul; 62(1):149-52. PubMed ID: 18390882 [TBL] [Abstract][Full Text] [Related]
40. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]